Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

AICAR Dosage Protocol | PeptideDosages.com

AICAR (50 mg Vial) Dosage Protocol AICAR Dosage Chart AICAR is dosed at 1 mg–3 mg daily via subcutaneous injection in educational protocols. A 50 mg vial reconstituted with bacteriostatic water yields about 16.7 mg/mL. This information is for research and educ

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

AICAR (50 mg Vial) Dosage Protocol

AICAR Dosage Chart

AICAR is dosed at 1 mg–3 mg daily via subcutaneous injection in educational protocols. A 50 mg vial reconstituted with bacteriostatic water yields about 16.7 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~16.7 mg/mL concentration.

Research dosing range: 1,000–3,000 mcg once daily (conservative gradual approach).

Easy measuring: At 16.7 mg/mL, 1 unit = 0.01 mL ≈ 167 mcg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks; avoid freeze–thaw cycles.

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a research compound that activates AMP-activated protein kinase (AMPK)[1], earning the nickname “exercise pill” after studies showed sedentary animals given AICAR experienced dramatic endurance improvements[2]. AICAR is prohibited in sports (WADA classifies it as a metabolic modulator) and is not approved for therapeutic use in humans[1]. This educational protocol presents a once-daily subcutaneous approach for research purposes only.

Related research: For distinct compound, component, or formulation evidence and safety context, read MOTS-c Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.

Standard / Gradual Approach (3 mL = ~16.7 mg/mL)

Weeks 1–2

1,000 mcg (1 mg)

6 units (0.06 mL)

Weeks 3–4

2,000 mcg (2 mg)

12 units (0.12 mL)

Weeks 5–8

3,000 mcg (3 mg)

18 units (0.18 mL)

Frequency: Inject once daily subcutaneously[3]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced Protocol (Higher Doses)

Weeks 3–6

Weeks 7–12

5,000 mcg (5 mg)

30 units (0.30 mL)

Note: Higher-dose protocols should only be considered when explicitly supported by literature[4]. Research doses remain well below human safety studies (up to 210 mg/kg IV)[5], providing a wide safety margin.

Supplies Needed

Plan based on an 8-week research protocol (conservative dosing).

Peptide Vials (AICAR, 50 mg each):

8 weeks (gradual 1–3 mg/day) ≈ 3 vials

12 weeks (2–5 mg/day advanced) ≈ 8 vials

Insulin Syringes (U-100, or 30/50-unit for precision):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (3 vials): 9 mL → 1 × 10 mL bottle

12 weeks (8 vials): 24 mL → 3 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100-count boxes

12 weeks: 168 swabs → recommend 2 × 100-count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Frequently Asked Questions About AICAR

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Source: peptidemind.com ↗
02Humanin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Humanin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Safety and Tolerability in the Research Setting

Safety and efficacy are separate questions, and it is entirely possible for a compound to be well tolerated while remaining unproven for the condition of interest. That is the current situation for NAD+ precursors in Parkinson’s disease. The short-term tolerability data, particularly for oral nicotinamide riboside, are reassuring within the limits of the trials conducted, but they are not a statement about long-term safety, about frail or elderly populations over years, or about drug interactions in people taking multiple Parkinson’s medications. The most directly relevant safety dataset is NR-SAFE, which was explicitly designed to probe tolerability at a high dose. Over four weeks, 3,000 mg of NR daily produced only mild adverse events, with no moderate or severe events and no significant excess over placebo; the most frequently reported events in the NR arm included extrapyramidal symptoms, headache, tremor, muscle cramps, fatigue, nausea, and dyspepsia, several of which overlap with the underlying disease and its treatment.2 The absence of painful flushing is notable because flushing is a classic dose-limiting effect of nicotinic acid (niacin); NR and nicotinamide generally avoid the flushing that niacin causes, which is one reason they are favored for chronic dosing. The lower-dose NADPARK trial similarly reported that 1,000 mg daily was well tolerated over 30 days.1 Broader supplement-safety literature on NR in non-Parkinson populations has generally supported tolerability at commonly studied doses, and NMN has likewise been reported to raise blood NAD+ safely in short studies of healthy adults.13 These reassurances come with substantial caveats that a careful reader should hold in mind. First, the trials are small and short. Twenty participants over four weeks, or thirty over one month, cannot detect uncommon adverse events or effects that only emerge with months to years of exposure, which is exactly the exposure that disease modification would require. Second, the populations were selected: early-stage, often newly diagnosed patients able to participate in a trial, not the full spectrum of advanced disease, multimorbidity, and polypharmacy seen in practice. Third, theoretical concerns exist that have not been resolved in humans. Because NAD+ metabolism intersects with cell proliferation and with the kynurenine pathway, and because some preclinical work has raised tissue-specific concerns about chronic high-dose precursor exposure (for example, questions about metabolite accumulation with sustained oral NMN in animal models), long-term safety cannot be assumed from short-term tolerability.13 Fourth, methylation load is a plausible consideration: clearance of excess nicotinamide consumes methyl groups, and the metabolic consequences of chronically high precursor intake over years are not well characterized in this population. There is also the matter of source and quality. In a research context, the identity, purity, and endotoxin status of a compound materially affect both the validity of an experiment and the safety of any handling. Injectable NAD+ preparations used outside regulated trials vary widely in provenance, and intravenous NAD+ administration in particular has been associated with infusion-related discomfort (nausea, chest tightness, flushing) that is typically managed by slowing the infusion rate but underscores that route and formulation matter.4 None of this constitutes clinical guidance. The appropriate summary is that oral NR appears well tolerated in the short term at the doses tested in early Parkinson’s trials, that other precursors and routes have thinner safety records, and that long-term safety in Parkinson’s disease specifically remains unestablished pending completed, published, adequately long trials.

Source: dosagepeptide.com ↗

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above. Journal of Medicinal Chemistry (ACS) — Bisubstrate inhibitors of NNMT with enhanced activity View Source PMC — NNMT: a bad actor in fat makes good in liver View Source Related research, protocols, and guides Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable. Research overview 5-Amino-1MQ Peptide: Benefits, Uses, Side Effects, Dosage, and Research Other vial-size protocols 5-Amino-1MQ (10 mg Vial) Dosage Protocol Practical guides Single Peptide Dosages Peptide Dosage & Reconstitution Calculator How to Reconstitute Peptides Syringe & Measurement Guide Peptide Storage Guide Peptide Dosage Chart

Source: peptidedosages.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Sample AICAR Dosing Protocol For Research

For reference purposes, here is a sample AICAR dosing protocol that researchers may administer to achieve benefits like enhanced endurance in test subjects: Daily Dosage: 25mg/daily Frequency: Daily subcutaneously. Study Duration: Up to two weeks Notes: Based on this protocol, a single two-week study requires a total of seven AICAR 50mg vials. Monitor kidney function throughout the whole period of the experiment. Given the potential for kidney damage at high dosage protocols, researchers should begin therapeutic protocols with significantly reduced doses, such as a maximum of 25mg/daily for a maximum duration of two weeks. As an alternative, subjects can be administered 50mg every other day for the same two-week period, achieving an equivalent total dosage. AICAR should not be cycled for longer than 14 days. Further, there should be a washout period of at least 1-2 months before reinitiating the cycle, and there should not be more than three cycles annually per subject.

Source: peptides.org ↗
Storage reference

Storage Instructions

Proper storage preserves compound stability. Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4]. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks. Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues. Do not refreeze reconstituted solution.

Source: peptidedosages.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →